Polypharmacy is associated with an increased risk of drug-drug interactions (DDIs), which can cause serious and debilitating drug-induced adverse events. With a steadily aging population and associated increasing multimorbidity and polypharmacy, the potential for DDIs becomes considerably important. Prostate cancer (PCa) is the most common cancer in men and occurs mostly in elderly men in the Western world. Therefore, the aim of this review is to give an overview of DDIs in PCa therapy to better understand pharmacodynamic and pharm kinetic side effects as well as their interactions with other medications. Last, we explore potential future strategies, which might help to optimize treatment and reduce adverse events patients with polypharmacy and PCa.
Clinical genitourinary cancer. 2019 May 27 [Epub ahead of print]
Doris Hebenstreit, Renate Pichler, Isabel Heidegger
Department of Urology, Medical University Innsbruck, Innsbruck, Austria., Department of Urology, Medical University Innsbruck, Innsbruck, Austria. Electronic address: .